Dioxomolybdenum(VI) complexes with pyrazole based aryloxide ligands: synthesis, characterization and application in epoxidation of olefins.

Synthesis, characterization, and epoxidation chemistry of four new dioxomolybdenum(VI) complexes [MoO(2)(L)(2)] (1-4) with aryloxide-pyrazole ligands L = L1-L4 is described. Catalysts 1-4 are air and moisture stable and easy to synthesize in only three steps in good yields. All four complexes are coordinated by the two bidentate ligands in an asymmetric fashion with one phenoxide and one pyrazole being trans to oxo atoms, respectively. This is in contrast to the structure found for the related aryloxide-oxazoline coordinated Mo(VI) dioxo complex 5. This was confirmed by the determination of the molecular structures of complexes 1-3 by X-ray diffraction analyses. Compounds 1-4 show high catalytic activities in the epoxidation of various olefins. Cyclooctene (S1) is converted to its epoxide with high activity, whereas the epoxidation of styrene (S2) is unselective. Internal olefins (S3 and S4) are also acceptable substrates, as well as the very challenging olefin 1-octene (S5). Catalyst loading can be reduced to 0.02 mol % and the catalyst can be recycled up to ten times without significant loss of activity. Supportive DFT calculations have been carried out in order to obtain deeper insights into the electronic situation around the Mo atom.

Oxorhenium(V) complexes with pyrazole based aryloxide ligands and application in olefin epoxidation.

We synthesized and characterized a set of new oxorhenium(V) complexes coordinated by various pyrazole containing phenol (L1-L3) and naphthol ligands (L4-L7). Depending on the starting material, we were able to selectively synthesize monosubstituded or disubstituted complexes of the type [ReOBr(2)L(PPh(3))] (1-7; L = L1-L7) and [ReOClL(2)] (L = L1 8; L2 9; L4 10; L6 11), respectively. All complexes are stable to air and moisture, both in solid state as well as in solution. Furthermore, the cationic oxorhenium(V) complex [ReO(L1)(2)(NCMe)](OTf) (8a) was obtained upon chloride abstraction with silver triflate from 8. All new complexes were able to catalyze the epoxidation of cis-cyclooctene in yields up to 64%. The ease of preparation and their tolerance to air and moisture, as well as the simple ligand modifications, make them an interesting class of novel catalysts. An attempted reduction of perchlorate ClO(4)(-) with complex 8 was unsuccessful. Molecular structures of complexes 1, 4, 6, 7, 8, 8a, 10, and 11 were determined by single crystal X-ray diffraction analyses.

Oxorhenium(V) complexes with ketiminato ligands: coordination chemistry and epoxidation of cyclooctene.

Rhenium(V) oxo complexes of the type [ReOX(L)(2)] (1-7; X = Cl, Br) containing beta-ketiminate ligands (L = CH(3)C(O)CH(2)C(NAr)CH(3): Ar = Ph (APOH), 2-MePh (MPOH), 2,6-Me(2)Ph (DPOH), 2,6-(i)Pr(2)Ph (DiPOH)) have been prepared by reaction of [ReOX(3)(OPPh(3))(SMe(2))] (X = Cl, Br) with the lithium salts of the corresponding ligands. All compounds have been spectroscopically characterized, showing [ReOX(DiPO)(2)] (X = Cl (1), Br (5)), [ReOX(DPO)(2)] (X = Cl (2), Br (6)), and [ReOX(APO)(2)] (X = Cl (4), Br (7)) to be isomerically pure, in contrast to complex [ReOCl(MPO)(2)] (3), which exhibits a mixture of isomers. Compounds 2, 3, 5, and 7 were crystallographically characterized, showing similar octahedral coordination spheres with trans O horizontal lineRe-O and cis O horizontal lineRe-Cl bonds. However, the coordination of the nitrogen atoms vs each other is found to be cis or trans. Compounds 2 and 5 showed a trans-N,N configuration, for compound 3 both isomers (trans-N,N 3 and cis-N,N 3) were structurally characterized, and 7 gave a cis-N,N configuration. Compounds 1-6 are catalyst precursors for the epoxidation of cis-cyclooctene with 3 equiv of tert-butyl hydroperoxide (TBHP). Yields of the formed epoxide were up to 55% with all precursors, except with 2 and 6, where only up to 13% of epoxide was obtained under analogous conditions.

Determination of selenosugars in crude human urine using high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.

The narrow gap between essentiality and toxicity of selenium requires detailed investigations on selenium metabolism in order to find suitable indicators for the selenium status in the human body. Current methods for quantitative selenium speciation in human urine are based on separation by high-performance liquid chromatography (HPLC) coupled online with elemental mass spectrometry (MS), and the potential of molecular MS detection techniques for the reliable identification and quantification of selenosugars in crude human urine has not been utilized. Now we report the development of an HPLC tandem mass spectrometric (MS/MS) method for the reliable determination in crude human urine of three significant selenium urinary metabolites, collectively termed selenosugars, namely methyl 2-acetamido-2-deoxy-1-seleno-beta-D-galactopyranoside (SeGalNAc), methyl 2-acetamido-2-deoxy-1-seleno-beta-D-glucopyranoside (SeGluNAc) and methyl 2-amino-2-deoxy-1-seleno-beta-D-galactopyranoside (SeGalNH2). Reversed-phase HPLC, with and without cation-exchange guard columns, was applied for the separation of the selenosugars, and atmospheric pressure chemical ionization (APCI) and selected reaction monitoring (SRM) were used for selective and sensitive detection. The collision-induced dissociation behaviour of the selenosugars was studied in detail using APCI triple quadrupole MS/MS and electrospray ion trap MS. The developed method was applied to urine samples collected prior to and after selenium supplementation for the quantification of SeGalNAc using both external calibration and the method of standard additions. Additionally, SeGalNH2 was detected in urine samples after Se supplementation. Finally, neutral loss scanning was explored as a possible method for the detection of unknown methyl-selenosugars.

Novel thioarsenic metabolites in human urine after ingestion of an arsenosugar, 2',3'-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-beta-D-riboside.

The presence of arsenic-containing carbohydrates, arsenosugars, in many seafoods raises questions of human health concerning the ingestion and metabolism of these compounds. A previous study investigating the metabolites in human urine after the ingestion of a common arsenosugar 2',3'-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-beta-d-riboside (oxo-arsenosugar) showed that the arsenic was rapidly excreted in the urine and was present as at least 12 metabolites, only three of which could be identified. In this repeat study with oxo-arsenosugar and using high-performance liquid chromatography/inductively coupled plasma mass spectrometry, we report the identification of seven arsenic metabolites, which together accounted for 88% of the total urinary arsenic collected over 61 h. The metabolites included previously reported human urinary arsenicals dimethylarsinate (DMA), oxo-dimethylarsenoethanol (oxo-DMAE), and trimethylarsine oxide, in addition to new human metabolites oxo-dimethylarsenoacetate (oxo-DMAA), thio-dimethlyarsenoacetate (thio-DMAA), thio-dimethylarsenoethanol (thio-DMAE), and the thio-arsenosugar. Cytotoxicity testing of the major metabolites DMA, oxo-DMAE, thio-DMAE, oxo-DMAA, and thio-DMAA showed that they were nontoxic even at 10 mM, except for DMA, which showed some toxic effects at 1 mM.

Selenium metabolites in human urine after ingestion of selenite, L-selenomethionine, or DL-selenomethionine: a quantitative case study by HPLC/ICPMS.

To obtain quantitative information on human metabolism of selenium, we have performed selenium speciation analysis by HPLC/ICPMS on samples of human urine from one volunteer over a 48-hour period after ingestion of selenium (1.0 mg) as sodium selenite, L-selenomethionine, or DL-selenomethionine. The three separate experiments were performed in duplicate. Normal background urine from the volunteer contained total selenium concentrations of 8-30 microg Se/L (n=22) but, depending on the chromatographic conditions, only about 30-70% could be quantified by HPLC/ICPMS. The major species in background urine were two selenosugars, namely methyl-2-acetamido-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 1) and its deacylated analog methyl-2-amino-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 3). Selenium was rapidly excreted after ingestion of the selenium compounds: the peak concentrations (approximately 250-400 microg Se/L, normalized concentrations) were recorded within 5-9 hours, and concentrations had returned to close to background levels within 48 hours, by which time 25-40% of the ingested selenium, depending on the species ingested, had been accounted for in the urine. In all experiments, the major metabolite was selenosugar 1, constituting either approximately 80% of the total selenium excreted over the first 24 hours after ingestion of selenite or L-selenomethionine or approximately 65% after ingestion of DL-selenomethionine. Selenite was not present at significant levels (<1 microg Se/L) in any of the samples; selenomethionine was present in only trace amounts (approximately 1 microg/L, equivalent to less than 0.5% of the total Se) following ingestion of L-selenomethionine, but it constituted about 20% of the excreted selenium (first 24 hours) after ingestion of DL-selenomethionine, presumably because the D form was not efficiently metabolized. Trimethylselenonium ion, a commonly reported urine metabolite, could not be detected (<1 microg/L) in the urine samples after ingestion of selenite or selenomethionine. Cytotoxicity studies on selenosugar 1 and its glucosamine isomer (selenosugar 2, methyl-2-acetamido-2-deoxy-1-seleno-beta-D-glucosopyranoside) were performed with HepG2 cells derived from human hepatocarcinoma, and these showed that both compounds had low toxicity (about 1000-fold less toxic than sodium selenite). The results support earlier studies showing that selenosugar 1 is the major urinary metabolite after increased selenium intake, and they suggest that previously accepted pathways for human metabolism of selenium involving trimethylselenonium ion as the excretionary end product may need to be re-evaluated.